First-Line Immunotherapy with Check-Point Inhibitors: Prospective Assessment of Cognitive Function.

Cancers (Basel) · 2023 · PMC10000599 · PMID 36900405

Europe PMC DOI

hedged sentence

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

approached significancep = 0.066so close (0.05 < p ≤ 0.1)

However, estimated differences for CPI Group participants’ MoCA-Blind test scores compared to the ADRC cognitively intact controls approached significance at baseline ( p = 0.066) and were significantly worse than the controls’ scores after CPI treatment (6 months for CPI Group participants’ scores compared to controls’ scores at 12 months, p = 0.011).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.